PATENT CLAIM ANALYSIS

Application Number: 15967970
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-08
Patent Classification: ["424", "450000"]

Abstract:
An object of the present invention is to provide a tumor therapeutic agent and a kit which have superior antitumor effects as compared with gemcitabine, a taxane antitumor agent, and a combination therapy thereof which have been put on the market. According to the present invention, there is provided a tumor therapeutic agent obtained by combining a taxane antitumor agent with a liposome composition in which gemcitabine or a salt thereof is contained in a liposome.

Claim (Index 3):
The tumor therapeutic agent according to  claim 1 ,\n wherein the taxane antitumor agent is nab-paclitaxel.

Metadata:
- Claim Count in Document: 13.0
- Percentile: 93.0
- Lexical Diversity: 1.76087
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['11131436', '15301570', '15335640', '12864280', '14888006']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7228440958587885
- 35 USC 102 Novelty (BERT): 0.5191156017673527
- Combined Prediction Score: 0.702471246449645
- Mean Citation Score: 181.076332
- Max Citation Score: 198.72923
- Similarity Product: 124.90757228039742

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test